Head-to-head evidence
salbutamol vs Salbutamol HFA-152a
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
salbutamol
Developed by GlaxoSmithKline
NCT03528577 · Phase 3 · completed
The study randomized 128 participants in a quadruple-blind, four-period crossover design with active and placebo comparators. However, its primary endpoint was a pharmacodynamic surrogate rather than a hard clinical outcome. Results were not posted at the time of grading; the key result shown was recorded subsequently from the registry record.
Next expected readout: June 2027 · NCT06473779 (registry estimate)
Salbutamol HFA-152a
Developed by GlaxoSmithKline
NCT06261957 · Phase 3 · completed
The trial randomized 477 participants and used quadruple blinding with an active salbutamol comparator. Its primary clinical safety endpoint was the number of participants with adverse events, but results are not posted, so whether the primary comparison was favorable cannot be determined.
Next expected readout: February 2027 · NCT06433921 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: salbutamol's landscape · Salbutamol HFA-152a's landscape